Advertisement
MGTX vs VYGR
Which Stock Would AI Choose? MeiraGTx Holdings (MGTX) vs. Voyager Therapeutics (VYGR) Stock Comparison
Key Takeaways
- MGTX has pivoted toward late-stage, near-commercial genetic-medicine programs, while VYGR remains an earlier-stage neurology platform reliant on collaborations and pipeline milestones.
- Recent market activity favors MGTX, which has outperformed the broader market, whereas VYGR has experienced sustained downward pressure over the trailing year.
- Regulatory momentum differs sharply: MGTX has secured FDA designations, while VYGR is still working toward first-in-human and clinical data milestones.
- Both carry biotechnology risk, but VYGR relies more heavily on partner milestones for revenue, whereas MGTX is moving toward independent commercialization.
- For more information on each company's latest developments and daily activity, explore the MGTX Major News and MGTX Today's Price Move pages, as well as the VYGR Major News and VYGR Today's Price Move pages.
- To see how automated strategies are positioning across these and thousands of other tickers, explore Trending AI Robots.
Introduction
Investors evaluating the biotechnology sector often weigh late-stage, near-commercial companies against earlier-stage platform plays, each offering a different balance of risk and catalyst potential. This stock comparison examines MGTX (MeiraGTx Holdings) and VYGR (Voyager Therapeutics), two genetic-medicine developers with overlapping therapeutic ambitions but very different market positioning. Both are followed by traders and long-term investors interested in gene therapy, neurology, and FDA catalyst events, yet their relative performance and fundamentals have recently diverged. Understanding these contrasts can help clarify which profile better aligns with a given investor's time horizon and risk tolerance.
MGTX Overview and Recent Performance
MeiraGTx Holdings is a vertically integrated, clinical-stage genetic medicines company developing therapies for ocular diseases, neurodegenerative conditions, and xerostomia (chronic dry mouth). In recent weeks, sentiment has been shaped by a reacquired asset, bota-vec, which the company took back from Johnson & Johnson to pursue regulatory submissions for X-linked retinitis pigmentosa (XLRP), a rare inherited retinal disease. The company has also reported positive three-year data from its AAV2-hAQP1 program in radiation-induced xerostomia and received a Breakthrough Therapy Designation (a designation that speeds FDA review for serious conditions) for that program.
Financially, MGTX posted a notable swing to profitability in a recent quarter, though much of that reflected milestone and financing-related items rather than recurring product revenue. Shares have risen meaningfully over the past year and have outperformed the S&P 500 for much of 2026. Analyst consensus remains a Buy, reflecting confidence in the company's late-stage pipeline and path toward potential commercial launches.
VYGR Overview and Recent Performance
Voyager Therapeutics is a biotechnology company focused on gene therapies for neurological diseases, anchored by its TRACER adeno-associated virus (AAV) capsid discovery platform, which is designed to improve delivery of genetic medicines across the blood-brain barrier. Its pipeline includes an anti-tau antibody (VY7523) for Alzheimer's disease, tau-silencing and SOD1-silencing gene therapy programs, and a Friedreich's ataxia candidate. Much of the company's funding comes through collaborations with partners such as Novartis and Neurocrine.
In recent market activity, VYGR has lagged significantly, with shares declining sharply over the trailing twelve months and trading near multi-year lows. Revenue remains modest and driven primarily by collaboration reimbursements, while the company continues to report net losses. On a positive note, Voyager maintains a substantial cash position—approximately $171.7 million as of the first quarter of 2026—with management indicating a runway into 2028. Analysts retain a broadly positive consensus, but near-term catalysts remain tied to early clinical data and partner milestones.
Trending AI Robots
Tickeron maintains a large library of AI trading bots that collectively monitor thousands of different tickers, each operating with its own trading style, strategy, timeframe, performance record, and target universe. Because market conditions change, only a small subset of these bots tends to align with the current environment, and Tickeron curates the best-performing and most relevant strategies in its dedicated Trending AI Robots section. This curated view highlights bots whose recent statistics—across win rate, drawdown, and trade frequency—reflect conditions suited to the present market. For investors tracking MGTX and VYGR, or seeking automated signals across the broader market, reviewing Trending AI Robots can offer a data-driven complement to manual analysis.
Head-to-Head Comparison
The two companies occupy different stages of the biotechnology lifecycle. MGTX is advancing late-stage and registration-ready programs, positioning itself for potential product launches and independent commercialization. VYGR, by contrast, is a platform company whose value hinges on validating its blood-brain barrier delivery technology and advancing earlier-stage neurology candidates, often through partner-funded development.
Growth drivers also differ. MeiraGTx's catalysts are regulatory filings and clinical data readouts for bota-vec and AAV2-hAQP1, while Voyager's catalysts center on Phase 1 data and partner milestones. Recent momentum strongly favors MGTX, which has gained ground over the trailing year, versus VYGR, which has faced sustained selling pressure. On the risk side, MeiraGTx carries execution risk tied to manufacturing, regulatory review, and the durability of recent earnings, while Voyager faces longer development timelines, cash-burn considerations, and dependence on collaborations.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst visibility, and relative market positioning, Tickeron's AI would likely favor MGTX in the current environment. The company's stronger relative performance, late-stage pipeline, recent regulatory designations, and shift toward near-term commercial milestones suggest more established momentum than VYGR, whose valuation remains tied to early-stage data and partnership outcomes. This assessment is probabilistic rather than definitive: both names carry meaningful biotechnology risk, and the balance could shift with new clinical data or regulatory developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MGTX is a StrongBuy and VYGR is a Hold.
MGTX in +6.21% Uptrend, advancing for three consecutive days on October 28, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MGTX advanced for three days, in 212 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for MGTX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for MGTX just turned positive on October 21, 2026. Looking at past instances where MGTX's MACD turned positive, the stock continued to rise in 29 of 40 cases over the following month. The odds of a continued upward trend are 73%.
MGTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGTX as a result. In 77 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for MGTX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.791) is normal, around the industry mean (2.788). P/E Ratio (9.562) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (2.715) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VYGR's RSI Oscillator ascends from oversold territory
The RSI Indicator for VYGR moved out of oversold territory on November 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 25 of the 28 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 62 cases where VYGR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for VYGR just turned positive on October 30, 2026. Looking at past instances where VYGR's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Following a +5.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where VYGR advanced for three days, in 228 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
VYGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for VYGR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.687) is normal, around the industry mean (2.788). P/E Ratio (-0.950) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. VYGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MGTX | VYGR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 16 | 98 | |
PRICE GROWTH RATING 1..100 | 63 | 86 | |
P/E GROWTH RATING 1..100 | 81 | 11 | |
SEASONALITY SCORE 1..100 | 50 | 46 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VYGR's Valuation (49) in the Biotechnology industry is in the same range as MGTX (80). This means that VYGR’s stock grew similarly to MGTX’s over the last 12 months.
VYGR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MGTX (100). This means that VYGR’s stock grew similarly to MGTX’s over the last 12 months.
MGTX's SMR Rating (16) in the Biotechnology industry is significantly better than the same rating for VYGR (98). This means that MGTX’s stock grew significantly faster than VYGR’s over the last 12 months.
MGTX's Price Growth Rating (63) in the Biotechnology industry is in the same range as VYGR (86). This means that MGTX’s stock grew similarly to VYGR’s over the last 12 months.
VYGR's P/E Growth Rating (11) in the Biotechnology industry is significantly better than the same rating for MGTX (81). This means that VYGR’s stock grew significantly faster than MGTX’s over the last 12 months.
| MGTX | VYGR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 81% | 1 day ago 89% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 87% |
| Momentum ODDS (%) | 1 day ago 80% | N/A |
| MACD ODDS (%) | 1 day ago 73% | 1 day ago 89% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 84% |
| Advances ODDS (%) | 10 days ago 83% | 3 days ago 83% |
| Declines ODDS (%) | 1 day ago 83% | 8 days ago 82% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 71% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MGTX’s FA Score shows that 1 FA rating(s) are green while VYGR’s FA Score has 1 green FA rating(s).
- MGTX’s FA Score: 1 green, 4 red.
- VYGR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MGTX’s TA Score shows that 5 TA indicator(s) are bullish while VYGR’s TA Score has 5 bullish TA indicator(s).
- MGTX’s TA Score: 5 bullish, 3 bearish.
- VYGR’s TA Score: 5 bullish, 2 bearish.
Price Growth
MGTX (@Biotechnology) experienced а -12.31% price change this week, while VYGR (@Biotechnology) price change was -2.27% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.83%. For the same industry, the average monthly price growth was -14.34%, and the average quarterly price growth was -21.24%.
Reported Earning Dates
MGTX is expected to report earnings on Nov 12, 2026.
VYGR is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-8.83% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
VYGR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VYGR has been loosely correlated with EDIT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if VYGR jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To VYGR | 1D Price Change % | ||
|---|---|---|---|---|
| VYGR | 100% | -8.02% | ||
| EDIT - VYGR | 60% Loosely correlated | -6.25% | ||
| RCKT - VYGR | 55% Loosely correlated | -6.70% | ||
| DYN - VYGR | 52% Loosely correlated | -6.36% | ||
| MGTX - VYGR | 50% Loosely correlated | -9.66% | ||
| SLDB - VYGR | 50% Loosely correlated | -5.21% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AUSM | 25.00 | 0.01 | +0.02% |
| Allspring Ultra Short Municipal ETF (AUSM) | |||
| INCM | 29.02 | -0.40 | -1.36% |
| Franklin Income Focus ETF (INCM) | |||
| SNOV | 27.16 | -0.70 | -2.51% |
| FT Vest U.S. Small Cap Moderate Buffer ETF - November (SNOV) | |||
| GDE | 52.28 | -1.46 | -2.72% |
| WisdomTree Efficient Gold Plus Equity Strategy Fund (GDE) | |||
| OWN | 23.38 | -0.78 | -3.22% |
| Inside Ownership 100 ETF (OWN) | |||